Over 72 weeks, nearly 63% of those who received semaglutide injections experienced resolution of MASH compared with around 34% of those who took a placebo
La mencin de un producto o ingrediente especfico en el sitio web del ODS no implica el respaldo del ODS, los NIH o el Departamento de Salud y Servicios Humanos de los Estados Unidos
There is also a higher chance of experiencing a localized immune reaction at the injection site
Sources Liu, L., Li, Z., Ye, W., Peng, P., Wang, Y., Wan, L., Li, J., Zhang, M., Wang, Y., Liu, R, Xu, D., & Zhang, J
Ensure that the medication is achieving the desired results, such as weight loss or improved blood sugar levels
[5] GLP-1 agonist market in the UK and Europe In the UK, the GLP-1 receptor agonist market reached a revenue of $847 million USD in 2024, with an expected revenue of $2.2 billion by 2030 and a CAGR of 16% between 2025 and 2030